Navigation Links
MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
Date:8/4/2008

WARREN, N.J., Aug. 4 /PRNewswire/ -- MonoSol Rx, a specialty pharmaceutical company leveraging its proprietary drug delivery technology to develop thin film pharmaceutical products, today announced the completion of pilot product development for its thin film formulation of escitalopram oxalate, a selective serotonin reuptake inhibitor. Escitalopram oxalate is indicated for depression and generalized anxiety disorders and is marketed under the brand name Lexapro(R). Lexapro generated sales of $2.1 billion in 2007.

Based on product development results, the Company is preparing to initiate bioequivalence trials to support marketing submissions in the US and Europe.

A. Mark Schobel, president and chief executive officer of MonoSol Rx, stated, "Our completion of prototype development has advanced our thin film escitalopram oxalate product to the clinical investigation stage of the project. Our proprietary PharmFilm(R) technology delivers thin-film drug products designed to offer significant patient benefits over other currently marketed prescription drug products and will help ensure that patients receive the appropriate dose in all treatment settings.

The Company is currently exploring potential partnerships to market their thin film formulation of escitalopram oxalate and expects to solidify an agreement prior to global regulatory submissions. The PharmFilm(R) escitalopram oxalate product should be available for marketing ahead of generic entrants expected in 2012, when Lexapro(R) loses patent exclusivity in the United States.

Keith Kendall, chief financial officer for MonoSol Rx, commented, "Our thin film formulation of escitalopram oxalate is one of the Company's self- funded initiatives designed to capitalize on our capacity to develop and manufacture thin film prescription products at commercial scale for a large pharmaceutical partner. As blockbuster drugs lose exclusivity, pharmaceutical companies are exploring alternative dosi
'/>"/>

SOURCE MonoSol Rx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
2. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
3. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
4. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
5. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
6. Pulmo BioTech Inc. Completes Bio-Distribution Studies
7. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
8. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
9. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
10. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
11. Pharmaxis Long-Term Safety Study of Bronchitol Completes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 24, 2014 Kinex Pharmaceuticals announced today ... at Roswell Park Cancer Institute. KX2-361 (KX02), ... that has shown potent inhibitory activity against a broad ... are resistant to Temozolomide (T98G), the most widely used ... well-established brain tumor mouse model, KX2-361 consistently clears brain ...
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... 2011 IBM (NYSE: IBM ) and ... NCD Challenge , a competition among a number ... of students to find new ways to address the rise ... (Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO ) Illnesses such ...
... bio-pharmaceutical companies lose the ability to communicate externally because ... internal Advocacy groups will become more important to a ... cost effectiveness of care by communicating concepts and arranging ... Since internal Advocacy groups are not known ...
Cached Medicine Technology:IBM Launches University Competition to Combat Growth of Non-Communicable Diseases 2IBM Launches University Competition to Combat Growth of Non-Communicable Diseases 3Pharmaceutical Advocacy Groups Focus on Value-of-Care Initiatives 2
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... mount in a mass tort litigation currently underway in ... reports. As of December 24, 2014, court documents ... proceeding on behalf of individuals who developed gynecomastia (male ... use. Data from the Court indicates that this represents ...
(Date:12/24/2014)... December 24, 2014 Dr. Vu Ho, ... expansion of his practice and med-spa with the addition ... growing list of cosmetic treatments and services. , “Silk ... the skin,” says Dr. Ho. “As a result it ... as wrinkles, sun spots, discolorations or blemishes.” , Similar ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Today, UWDress.com, the ... long sleeve wedding gowns, and launched a site-wide wedding gown ... long sleeve wedding gowns in a more unexpected way, the ... company are popular in the global market, and they are ... at UWDress.com are offered at discounted prices, up to 75% ...
(Date:12/24/2014)... Dallas, TX (PRWEB) December 25, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. Stivarga is a drug which is ... This drug is orally administered and is also prescribed ... The drug which is FDA approved is a multi-kinase ...
Breaking Medicine News(10 mins):Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... A team of scientists has found a way to induce nerve ... to protect the cells from the damage // caused by stress ... on a compound found in the body. The findings might give ... as Alzheimer’s. ,This approach works by inducing nerve cells ...
... detected in Australia. An elderly woman died on 8th January at ... of cancer // . She was tested positive for Listeria. ... health care officials in Australia. This woman came from interstate and ... the hospital authorities say that the cause of death cannot be ...
... is reported to be on the decline. The current winter figures are ... figure // has been on the decline since 2001. The threat from ... to be the immunity that the people in the country have gained ... every year. ,Most of the infected in the current ...
... There is a greater chance of people who undergo a ... new research which correlated simultaneous changes // in blood ... of what is known about the brain and its links ... on animals. But the new study on humans used functional ...
... the mantra, “Be healthy, be vegetarian!” This is inferred by ... rich in veggies, whole grains and fruits to promote good ... of researchers of London's Imperial College. Their findings were that ... more likely to maintain better cardiovascular health than their carnivorous ...
... and insects might have a lot in common while gaining fat. ... when it comes to fat formation in the case of mice ... reveals the effect that genes have on fat storage. The Hh ... are meant for the bone or fat. ,The ...
Cached Medicine News:Health News:Therapy inducing self-repair of nerves to help Alzheimer’ 2Health News:Several helping of fruits and vegetables help the pressure off the pump- the heart! 2
10:1 Zoom Ratio - The parallel optical system of the SMZ-1000 has a 10:1 zoom with clickstops at 1X intervals. It features a zoom range of 0.8X to 8.0X and total magnification (depending on eyepieces...
Fixed Versatility - With a diverse selection of body tubes, stands, lighting techniques and Nikon's world-renowned optics, this modular microscope can be configured to fit nearly any application....
... a zoom ratio of 15:1, ... to 11.25X, and the convenience ... from 1X to 11X, observation ... of 3.75X to 540X can ...
... 40x/1.2W Corr was designed to have the ... aqueous specimens (vital sections, cell cultures, specimens ... compensating differences in cover glass thickness (0.14...0.18 ... 37C). The correction collar can also ...
Medicine Products: